Oracle Corporation vs Revvity Inc — how do they compare? Oracle Corporation trades at $141.53 (market cap $411.34B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Oracle Corporation is far larger — about 24.2× Revvity Inc's market cap, and Oracle Corporation pays the higher dividend (1.47%). Which is the better fit depends on your goals — on Pluang, investors hold Oracle Corporation for 72 Days and Revvity Inc for 12 Days on average.
| ORCL | RVTY | |
|---|---|---|
Market Cap | $411.34B | $16.98B |
Volume | 41,276,815 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $313.00 | $157.36 |
52-Week Low | $114.99 | $82.26 |
Typical Hold Time | 72 Days | 12 Days |
Enterprise Value | $535.15B | $19.30B |
Dividend Yield | 1.47% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Oracle Corporation (ORCL) is trading at $135.56, down 5.58% amid broader market volatility despite strong Q1 2026 earnings that beat expectations with EPS of $2.11 versus $1.96. The stock faces technical bearish signals with support at $133 and resistance at $141, while fundamentals show robust revenue growth to $57.4B in 2025 and net income margin expansion to 26.36%. Recent AI-driven infrastructure investments and layoffs highlight strategic shifts to capitalize on cloud demand.
Oracle's outlook remains positive with analyst consensus price target of $236.52 implying 74% upside, supported by 65% buy ratings. Key opportunities include AI cloud revenue growth accelerating 120% in Q1 2026, though risks persist from high debt levels ($85.3B long-term) and sensitivity to Fed policy given the stock's 1.9 beta. Investors should weigh strong profitability against execution risks in aggressive data center expansion.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →